JP3831255B2 - ４−ベンジル−１−〔２−（４−ヒドロキシフェノキシ）エチル〕ピペリジン−３，４−ジオール - Google Patents

４−ベンジル−１−〔２−（４−ヒドロキシフェノキシ）エチル〕ピペリジン−３，４−ジオール Download PDF

Info

Publication number
JP3831255B2
JP3831255B2 JP2001578404A JP2001578404A JP3831255B2 JP 3831255 B2 JP3831255 B2 JP 3831255B2 JP 2001578404 A JP2001578404 A JP 2001578404A JP 2001578404 A JP2001578404 A JP 2001578404A JP 3831255 B2 JP3831255 B2 JP 3831255B2
Authority
JP
Japan
Prior art keywords
benzyl
piperidine
ethyl
diol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001578404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509837A (ja
JP2004509837A5 (enExample
Inventor
アラニン，アレキザンダー
ビュッテルマン，ベルント
ハイツ・ニダール，マリー−ポール
ヤーシュケ，ゲオルク
ピナール，エマニュエル
ワイラー，レネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004509837A publication Critical patent/JP2004509837A/ja
Publication of JP2004509837A5 publication Critical patent/JP2004509837A5/ja
Application granted granted Critical
Publication of JP3831255B2 publication Critical patent/JP3831255B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2001578404A 2000-04-25 2001-04-17 ４−ベンジル−１−〔２−（４−ヒドロキシフェノキシ）エチル〕ピペリジン−３，４−ジオール Expired - Fee Related JP3831255B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
PCT/EP2001/004305 WO2001081309A2 (en) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol

Publications (3)

Publication Number Publication Date
JP2004509837A JP2004509837A (ja) 2004-04-02
JP2004509837A5 JP2004509837A5 (enExample) 2005-01-27
JP3831255B2 true JP3831255B2 (ja) 2006-10-11

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001578404A Expired - Fee Related JP3831255B2 (ja) 2000-04-25 2001-04-17 ４−ベンジル−１−〔２−（４−ヒドロキシフェノキシ）エチル〕ピペリジン−３，４−ジオール

Country Status (18)

Country Link
US (1) US6432985B2 (enExample)
EP (1) EP1278730B1 (enExample)
JP (1) JP3831255B2 (enExample)
KR (1) KR100527527B1 (enExample)
CN (1) CN1178914C (enExample)
AR (1) AR028357A1 (enExample)
AT (1) ATE313527T1 (enExample)
AU (1) AU785153B2 (enExample)
BR (1) BR0110233A (enExample)
CA (1) CA2407345C (enExample)
DE (1) DE60116080T2 (enExample)
DK (1) DK1278730T3 (enExample)
ES (1) ES2254422T3 (enExample)
MX (1) MXPA02010573A (enExample)
PE (1) PE20011229A1 (enExample)
UY (1) UY26681A1 (enExample)
WO (1) WO2001081309A2 (enExample)
ZA (1) ZA200208134B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
RU2497819C2 (ru) * 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
NZ588698A (en) * 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
DK2324126T3 (da) 2008-08-12 2014-06-16 Zinfandel Pharmaceuticals Inc FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN103501783A (zh) 2011-01-10 2014-01-08 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN109790149B (zh) * 2016-11-08 2022-05-17 豪夫迈·罗氏有限公司 苯氧基三唑类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
CN1443166A (zh) 2003-09-17
MXPA02010573A (es) 2003-03-10
EP1278730B1 (en) 2005-12-21
CA2407345C (en) 2009-04-07
US20010047014A1 (en) 2001-11-29
UY26681A1 (es) 2001-10-25
DK1278730T3 (da) 2006-05-01
ATE313527T1 (de) 2006-01-15
CA2407345A1 (en) 2001-11-01
ES2254422T3 (es) 2006-06-16
AU785153B2 (en) 2006-10-05
ZA200208134B (en) 2004-01-22
JP2004509837A (ja) 2004-04-02
KR20040007216A (ko) 2004-01-24
PE20011229A1 (es) 2001-12-08
EP1278730A2 (en) 2003-01-29
KR100527527B1 (ko) 2005-11-09
DE60116080T2 (de) 2006-08-24
BR0110233A (pt) 2003-01-21
DE60116080D1 (de) 2006-01-26
WO2001081309A2 (en) 2001-11-01
CN1178914C (zh) 2004-12-08
US6432985B2 (en) 2002-08-13
AU6021301A (en) 2001-11-07
AR028357A1 (es) 2003-05-07
WO2001081309A3 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
JP3831255B2 (ja) ４−ベンジル−１−〔２−（４−ヒドロキシフェノキシ）エチル〕ピペリジン−３，４−ジオール
EP3474845B1 (en) Immunomodulator compounds
DE69622532T2 (de) Glycoprotein iib/iiia-antagonisten
DE69326160T2 (de) 4-carboxamidopiperidinderivate, zwischenprodukte und verwendung als neurokinin antagonisten
DE69623899T2 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
JP2000500786A (ja) エーテルムスカリン様アンタゴニスト
JPS63201196A (ja) アデノシン５’−カルボキサミド誘導体及びその製造方法
JP2866743B2 (ja) 神経保護化合物
JP3645856B2 (ja) エタンスルホニル−ピペリジン誘導体
EP4486720A1 (en) Aryl alkynamide derivatives
DE60204046T2 (de) N-heterocyclylhydrazide als neurotrophe mittel
HK40007517B (en) Immunomodulator compounds
HK40007517A (en) Immunomodulator compounds
JPWO1999052894A1 (ja) 血小板凝集阻害作用を有する含窒素複素環化合物およびその医薬用途

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060713

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090721

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100721

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110721

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees